ArticleViruses2024
The Changing Detection Rate of Respiratory Syncytial Virus in Adults in Western Australia between 2017 and 2023.
Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Changes in the Epidemiology of Influenza and Respiratory Syncytial Virus During 2020-2022 Relative to the Pre-COVID-19 Pandemic Period (2017-2020) From Systematic Sentinel Syndromic Surveillance in South Africa.Influenza and other respiratory viruses · 2026Article
- Respiratory syncytial virus epidemiology and effectiveness of infant nirsevimab: 2024 results from the Australian Sentinel Hospital Network (FluCAN-PAEDS).Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Article
- In-Hospital Death and Risk Factors in Adults With Respiratory Syncytial Virus in Spain (2016-2023). A Cross-Sectional Study With Focus on Older Patients.Health science reports · 2025Article
- Risk Groups for Vaccine-Preventable Respiratory Infections in Children and Adults: An Overview of the Australian Environment.Vaccines · 2025Review
- Determinants of respiratory syncytial virus and human metapneumovirus transmission.Clinical microbiology reviews · 2025Review
- Respiratory Syncytial Virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab Prophylaxis.Open forum infectious diseases · 2025Article
- Respiratory Syncytial Virus and Human Metapneumovirus Respiratory Hospitalizations and Outcomes in Colorado Adults ≥50 Years of Age: 2016-2023.The Journal of infectious diseases · 2025Article
- Strength and Durability of Respiratory Syncytial Virus Prefusion F Immunoglobulin G Following Infection and Exposure in a Household Cohort, 2014-2022.The Journal of infectious diseases · 2025Article
- RSV: an update on prevention and management.Australian prescriber · 2025Review
- Estimated Incidence of Hospitalisations and Deaths Attributable to Respiratory Syncytial Virus Infections in Adults in Australia Between 2010 and 2019.Influenza and other respiratory viruses · 2025Article
- Clinical characteristics of children hospitalized with cellulitis in Spain (2016-2022). A population-based analysis.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of respiratory syncytial virus (RSV) in adults is inadequately defined and the impact of SARS-CoV-2-related non-pharmaceutical interventions (NPIs) is underexplored. Using laboratory data, we described the detection rate of RSV in adults ≥16 years in Western Australia (WA) between 2017 and 2023. With the exception of 2020, RSV detections rose annually between 2017 and 2023, reaching 50.7 per 100,000 in 2023 (95% confidence interval [CI], 47.9-53.8). RSV testing expanded considerably across the study period, with the testing in 2023 more than five times the 2017 total. The detection rate was highest in adults ≥60 years between 2017 and 2019, particularly those ≥75 years. Following 2020, the detections in all age groups increased, with the highest detection rate in 2023 in those ≥75-years (199.5 per 100,000; 95% CI, 180.5-220). NPIs significantly impacted RSV seasonality; the preceding winter pattern was disrupted, resulting in an absent 2020 winter season and two major summer seasons in 2020/21 and 2021/22. The RSV season began to realign in 2022, reverting to a winter seasonal pattern in 2023 and the largest season in the study period. Ongoing surveillance will be required to understand the stability of these increases and to delineate the impact of new immunisation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.